Sangamo’s bankruptcy proceedings are driving deal-making across the Fabry space, with PTC’s winning bid for the program and Eli Lilly receiving a technology purchase for $50 million. The reported package positions Lilly to maintain a role in the underlying gene therapy platform while PTC takes on the clinical development and potential commercialization track. The auction dynamics underline how gene therapy portfolios can shift quickly when financing, timelines, and regulatory exposure converge. For investors and developers, Fabry is a benchmark indication where any regulatory acceleration can translate into fast commercial momentum. The Lilly technology stake also reflects continued platform interest even as specific programs change hands. With a near-term approval possibility on the horizon, ownership clarity becomes a competitive advantage. Going forward, late-stage trial continuity, regulatory interactions, and manufacturing transfer will likely determine how smoothly the programs progress post-auction.